Loncipoetin alfa (NuPIAO) vs Pegmolesatide (HS-20039)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline

Loncipoetin alfa (NuPIAO)

Marketed by Shenyang Sunshine Pharmaceutical

Phase 3 in Chronic Kidney Diseasebiologic
Partial signal

NCT05211167 · Phase 3 · status unknown

This is a randomized, active-controlled Phase 3 trial with an adequately sized enrollment comparing the study drug against a standard recombinant erythropoietin, using change in hemoglobin, the measure that defines the anemia being treated, as its primary endpoint. However, the trial was not blinded, and results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

Reported efficacy

hemoglobin concentration (25th-32nd week): Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given. (met)

Result source: NCT05211167

Pegmolesatide (HS-20039)

Marketed by Hansoh Pharmaceutical Group

Phase 3 in Chronic Kidney Diseasebiologic (pegylated EPO-mimetic peptide)
Reliable signal

NCT03902691 · Phase 3 · completed

This randomized, double-blind trial compared pegmolesatide directly against an active comparator, epoetin alfa, rather than placebo. Its prespecified non-inferiority comparison on hemoglobin change was met, with the between-group difference confidence interval falling entirely within the specified margin.

Next expected readout: December 2026 · NCT06946394 (registry estimate)

Reported efficacy

The mean change from the baseline hemoglobin level to the mean level during the evaluation period (Week 17-24): Mean Hb change from baseline: pegmolesatide +19.2 g/L vs epoetin alfa +15.4 g/L; between-group difference 3.8 g/L (95% CI 0.7-6.9), noninferiority margin -10 g/L (met)

Result source: NCT03903809

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLoncipoetin alfa (NuPIAO)Pegmolesatide (HS-20039)
Kidney composite outcome—Not reported—Not posted · NCT03902691
UACR, % change—Not reported—Not posted · NCT03902691
eGFR slope—Not reported—Not posted · NCT03902691
Haemoglobin, change—Not reported0.1 vs -0.2avs epoetin alfaNCT03902691

Kidney composite outcome

Loncipoetin alfa (NuPIAO)
—Not reported
Pegmolesatide (HS-20039)
—Not posted · NCT03902691

UACR, % change

Loncipoetin alfa (NuPIAO)
—Not reported
Pegmolesatide (HS-20039)
—Not posted · NCT03902691

eGFR slope

Loncipoetin alfa (NuPIAO)
—Not reported
Pegmolesatide (HS-20039)
—Not posted · NCT03902691

Haemoglobin, change

Loncipoetin alfa (NuPIAO)
—Not reported
Pegmolesatide (HS-20039)
0.1 vs -0.2avs epoetin alfaNCT03902691
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Loncipoetin alfa (NuPIAO)
Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given. NCT05211167 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pegmolesatide (HS-20039)

Hemoglobin Change g/dL 0.07 vs -0.22 epoetin alfa g/dL
absolute change · g/dL
NCT03902691 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loncipoetin alfa (NuPIAO)'s landscape · Pegmolesatide (HS-20039)'s landscape